loanDepot (LDI) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates


Exxon Mobil (XOM) reported $84.34 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 11.6%. EPS of $2.48 for the same period compares to $3.40 a year ago.

The reported revenue represents a surprise of -8.14% over the Zacks Consensus Estimate of $91.81 billion. With the consensus EPS estimate being $2.21, the EPS surprise was +12.22%.

While investors closely watch year-over-year changes in headline numbers — revenue and earnings — and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company’s underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock’s price performance.

Here is how Exxon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Oil-equivalent production per day: 3,824 KBOE/D versus the six-analyst average estimate of 3,769.47 KBOE/D.
  • Natural gas production available for sale per day – Worldwide: 7,645 Mcf/D compared to the 7,815.52 Mcf/D average estimate based on five analysts.
  • Net production of crude oil, natural gas liquids, bitumen and synthetic oil per day – Worldwide: 2550 thousands of barrels of oil compared to the 2475.58 thousands of barrels of oil average estimate based on five analysts.
  • Natural gas production available for sale per day – Asia: 3,486 Mcf/D compared to the 3,585.2 Mcf/D average estimate based on four analysts.
  • Chemical Products sales- United States: $1.74 billion versus the three-analyst average estimate of $1.79 billion.
  • Chemical Products sales- Non-U.S. $3.03 billion versus the three-analyst average estimate of $3.40 billion.
  • Specialty Products sales- Worldwide: $1.84 billion compared to the $1.87 billion average estimate based on three analysts.
  • Specialty Products sales- United States: $473 million versus the three-analyst average estimate of $486.69 million.
  • Specialty Products sales- Non-U.S. $1.37 billion versus the three-analyst average estimate of $1.38 billion.
  • Revenues- Sales and other operating revenue: $81.69 billion versus the five-analyst average estimate of $92.81 billion. The reported number represents a year-over-year change of -12.3%.
  • Revenues- Income from equity affiliates: $1.17 billion compared to the $1.31 billion average estimate based on three analysts. The reported number represents a change of +92.6% year over year.
  • Revenues- Other income: $1.49 billion versus the three-analyst average estimate of $1.07 billion. The reported number represents a year-over-year change of -10.2%.

View all Key Company Metrics for Exxon here>>>

Shares of Exxon have returned +0.1% over the past month versus the Zacks S&P 500 composite’s +2.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Just Released: Zacks Top 10 Stocks for 2024

Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.

See New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exxon Mobil Corporation (XOM) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



Image and article originally from www.nasdaq.com. Read the original article here.

By Zacks